Pacira BioSciences Reports Strong 2025 Financials, Defends Board Against DOMA Challenge

Event summary

  • Pacira BioSciences reported record 2025 revenue of $726.4 million, with GAAP gross margins of 79.4% and non-GAAP gross margins of 81.2%.
  • EXPAREL volume growth accelerated to 8% in the second half of 2025, nearly doubling the first half of the year.
  • Pacira has returned $200 million to stockholders since April 2025 under a $300 million share repurchase program.
  • The company reached a favorable, volume-limited settlement in the multi-year EXPAREL patent litigation, securing exclusivity through 2030.
  • Pacira's board has added five new independent directors since October 2023 and nominated a sixth for election at the Annual Meeting.

The big picture

Pacira BioSciences is positioning itself as a leader in non-opioid pain therapies, with a strong financial performance in 2025 and a strategic focus on long-term growth. The company's defense against DOMA's board challenge highlights the importance of governance in executing its 5x30 strategy. The broader industry trend towards non-opioid solutions and the company's pipeline advancements are key factors to watch in the coming years.

What we're watching

Governance Dynamics
Whether Pacira's board can maintain its independence and strategic oversight amid DOMA's challenge.
Execution Risk
The pace at which Pacira can advance its pipeline, particularly PCRX-201 and PCRX-2002, to meet market expectations.
Financial Strategy
How Pacira's share repurchase program and capital allocation will impact its long-term growth and stockholder value.